Induction of apoptosis by luteolin involving Akt inactivation in human 786-O renal cell carcinoma cells

Evidence-based Complementary and Alternative Medicine

Volumn 2013, Issue , 2013, Pages

  Ou, Yen Chuan ^a   Kuan, Yu Hsiang ^b   Li, Jian Ri ^a   Raung, Shue Ling ^a   Wang, Chung Chiang ^a   Hung, Yu Yeh ^a   Chen, Chun Jung ^a,c,d,e  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c TUNGHAI UNIVERSITY   (Taiwan)

^d NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^e HUNGKUANG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; APOPTOSIS SIGNAL REGULATING KINASE 1; HEAT SHOCK PROTEIN 90; L 9283; LUTEOLIN; MITOGEN ACTIVATED PROTEIN KINASE P38; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; TANESPIMYCIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CELL DEATH; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; UPREGULATION;

EID: 84874511787     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2013/109105     Document Type: Article

References (49)

1. Birt D. F., Hendrich S., Wang W., Dietary agents in cancer prevention: flavonoids and isoflavonoids. Pharmacology and Therapeutics 2001 90 2-3 157 177 2-s2.0-0034807826 10.1016/S0163-7258(01)00137-1 (Pubitemid 32913477)
2. Li Y., Fang H., Xu W., Recent advance in the research of flavonoids as anticancer agents. Mini-Reviews in Medicinal Chemistry 2007 7 7 663 678 2-s2.0-34547117859 10.2174/138955707781024463 (Pubitemid 47099168)
3. Ramos S., Effects of dietary flavonoids on apoptotic pathways related to cancer chemoprevention. The Journal of Nutritional Biochemistry 2007 18 7 427 442 2-s2.0-34249882770 10.1016/j.jnutbio.2006.11.004 (Pubitemid 46874924)
4. Lee H. J., Wang C. J., Kuo H. C., Chou F. P., Jean L. F., Tseng T. H., Induction apoptosis of luteolin in human hepatoma HepG2 cells involving mitochondria translocation of Bax/Bak and activation of JNK. Toxicology and Applied Pharmacology 2005 203 2 124 131 2-s2.0-13844275033 10.1016/j.taap.2004. 08.004 (Pubitemid 40248368)
5. Cheng A. C., Huang T. C., Lai C. S., Kuo J. M., Huang Y. T., Lo C. Y., Ho C. T., Pan M. H., Pyrrolidine dithiocarbamate inhibition of luteolin-induced apoptosis through up-regulated phosphorylation of akt and caspase-9 in human leukemia HL-60 cells. Journal of Agricultural and Food Chemistry 2006 54 12 4215 4221 2-s2.0-33745755792 10.1021/jf060269n (Pubitemid 44013324)
6. Ong C. S., Zhou J., Ong C. N., Shen H. M., Luteolin induces G1 arrest in human nasopharyngeal carcinoma cells via the Akt-GSK-3 β -Cyclin D1 pathway. Cancer Letters 2010 298 2 167 175 2-s2.0-77957963491 10.1016/j.canlet.2010.07.001
7. Choi A. Y., Choi J. H., Yoon H., Hwang K. Y., Noh M. H., Choe W., Yoon K. S., Ha J., Yeo E. J., Kang I., Luteolin induces apoptosis through endoplasmic reticulum stress and mitochondrial dysfunction in Neuro-2a mouse neuroblastoma cells. European Journal of Pharmacology 2011 668 1-2 115 126 10.1016/j.ejphar.2011.06.047
8. Lin Y. S., Tsai P. H., Kandaswami C. C., Cheng C. H., Ke F. C., Lee P. P., Hwang J. J., Lee M. T., Effects of dietary flavonoids, luteolin, and quercetin on the reversal of epithelial-mesenchymal transition in A431 epidermal cancer cells. Cancer Science 2011 102 10 1829 1839 10.1111/j.1349-7006.2011. 02035.x
9. Tang X., Wang H., Fan L., Wu X., Xin A., Ren H., Wang X. J., Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs. Free Radical Biology and Medicine 2011 50 11 1599 1609 2-s2.0-79955612814 10.1016/j.freeradbiomed.2011.03.008
10. Bai L., Xu X., Wang Q., Xu S., Ju W., Wang X., Chen W., He W., Tang H., Lin Y., A superoxide-mediated mitogen-activated protein kinase phosphatase-1 degradation and c-Jun NH2-terminal kinase activation pathway for luteolin-induced lung cancer cytotoxicity. Molecular Pharmacology 2012 81 4 549 555 10.1124/mol.111.076653
11. Rao P. S., Satelli A., Moridani M., Jenkins M., Rao U. S., Luteolin induces apoptosis in multidrug resistant cancer cells without affecting the drug transporter function: involvement of cell line-specific apoptotic mechanisms. International Journal of Cancer 2012 130 11 2703 2714 10.1002/ijc.26308
12. Coppin C., Porzsolt F., Awa A., Kumpf J., Coldman A., Wilt T., Immunotherapy for advanced renal cell cancer. Cochrane Database of Systematic Reviews 2005 1 CD001425 2-s2.0-18944385751
13. Rini B. I., Campbell S. C., Escudier B., Renal cell carcinoma. The Lancet 2009 373 9669 1119 1132 2-s2.0-62849128369 10.1016/S0140-6736(09)60229-4
14. Motzer R. J., Bukowski R. M., Targeted therapy for metastatic renal cell carcinoma. Journal of Clinical Oncology 2006 24 35 5601 5608 2-s2.0-33846821872 10.1200/JCO.2006.08.5415 (Pubitemid 46631341)
15. Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., Kapoor A., Staroslawska E., Sosman J., McDermott D., Bodrogi I., Kovacevic Z., Lesovoy V., Schmidt-Wolf I. G., Barbarash O., Gokmen E., O.'Toole T., Lustgarten S., Moore L., Motzer R. J., Global ARCC Trial. Temsirolimus, interferon alpha, or both for advanced renal-cell carcinoma. The New England Journal of Medicine 2007 356 22 2271 2281 10.1056/NEJMoa066838 (Pubitemid 46849157)
16. Larkin J. M. G., Ferguson T. R., Pickering L. M., Edmonds K., James M. G., Thomas K., Banerji U., Berns B., De Boer C., Gore M. E., A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma. British Journal of Cancer 2010 103 8 1149 1153 2-s2.0-77958007059 10.1038/sj.bjc.6605889
17. Gore M. E., Hariharan S., Porta C., Bracarda S., Hawkins R., Bjarnason G. A., Oudard S., Lee S. H., Carteni G., Nieto A., Yuan J., Szczylik C., Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer 2011 117 3 501 509 2-s2.0-79251478764 10.1002/cncr.25452
18. Huijts C. M., Santegoets S. J., van den Eertwegh A. J., Pijpers L. S., Haanen J. B., de Gruijl T. D., Verheul H. M., van der Vliet H. J., Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer. BMC Cancer 2011 11 article 505 10.1186/1471-2407-11-505
19. Roulin D., Waselle L., Dormond-Meuwly A., Dufour M., Demartines N., Dormond O., Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib. Molecular Cancer 2011 10 article 90 2-s2.0-79960683561 10.1186/1476-4598-10-90
20. Xia Z., Dickens M., Raingeaud J., Davis R. J., Greenberg M. E., Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995 270 5240 1326 1331 2-s2.0-0028880006
21. Garrington T. P., Johnson G. L., Organization and regulation of mitogen-activated protein kinase signaling pathways. Current Opinion in Cell Biology 1999 11 2 211 218 2-s2.0-0032910168 10.1016/S0955-0674(99)80028-3 (Pubitemid 29164036)
22. Zhang R., Luo D., Miao R., Bai L., Ge Q., Sessa W. C., Min W., Hsp90-Akt phosphorylates ASK1 and inhibits ASK1-mediated apoptosis. Oncogene 2005 24 24 3954 3963 2-s2.0-20544446881 10.1038/sj.onc.1208548 (Pubitemid 40896407)
23. Takano Y., Iwata H., Yano Y., Miyazawa M., Virgona N., Sato H., Ueno K., Yano T., Up-regulation of connexin 32 gene by 5-aza-2′-deoxycytidine enhances vinblastine-induced cytotoxicity in human renal carcinoma cells via the activation of JNK signalling. Biochemical Pharmacology 2010 80 4 463 470 2-s2.0-77953915322 10.1016/j.bcp.2010.05.016
24. Fujita M., Yagami T., Fujio M., Tohji C., Takase K., Yamamoto Y., Sawada K., Yamamori M., Okamura N., Cytotoxicity of troglitazone through PPAR γ -independent pathway and p38 MAPK pathway in renal cell carcinoma. Cancer Letters 2011 312 2 219 227 10.1016/j.canlet.2011.08.010
25. Ou Y. C., Yang C. R., Cheng C. L., Raung S. L., Hung Y. Y., Chen C. J., Indomethacin induces apoptosis in 786-O renal cell carcinoma cells by activating mitogen-activated protein kinases and AKT. European Journal of Pharmacology 2007 563 1-3 49 60 2-s2.0-34247092489 10.1016/j.ejphar.2007.01.071 (Pubitemid 46602228)
26. Chang C. Y., Shen C. C., Su H. L., Chen C. J., Gefitinib induces apoptosis in human glioma cells by targeting Bad phosphorylation. Journal of Neurooncology 2011 105 3 507 522 10.1007/s11060-011-0632-3
27. Kim A. H., Khursigara G., Sun X., Franke T. F., Chao M. V., Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Molecular and Cellular Biology 2001 21 3 893 901 2-s2.0-0035133227 10.1128/MCB.21.3.893-901.2001 (Pubitemid 32104737)
28. Choi T. G., Lee J., Ha J., Kim S. S., Apoptosis signal-regulating kinase 1 is an intracellular inducer of p38 MAPK-mediated myogenic signalling in cardiac myoblasts. Biochimica et Biophysica Acta 2011 1813 8 1412 1421 2-s2.0-79959334421 10.1016/j.bbamcr.2011.04.001
29. Beck R., Verrax J., Gonze T., Zappone M., Pedrosa R. C., Taper H., Feron O., Calderon P. B., Hsp90 cleavage by an oxidative stress leads to its client proteins degradation and cancer cell death. Biochemical Pharmacology 2009 77 3 375 383 2-s2.0-58649121962 10.1016/j.bcp.2008.10.019
30. +3-induced apoptosis through inhibition of telomerase activity via JNK activation. Toxicology and Applied Pharmacology 2008 229 2 239 251 2-s2.0-43449105876 10.1016/j.taap.2008.01.018
31. Ichijo H., Nishida E., Irie K., Ten Dijke P., Saitoh M., Moriguchi T., Takagi M., Matsumoto K., Miyazono K., Gotoh Y., Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 1997 275 5296 90 94 2-s2.0-14444281569 10.1126/science.275.5296.90 (Pubitemid 27020316)
32. Matsukawa J., Matsuzawa A., Takeda K., Ichijo H., The ASK1-MAP kinase cascades in mammalian stress response. Journal of Biochemistry 2004 136 3 261 265 2-s2.0-9144253936 10.1093/jb/mvh134 (Pubitemid 39545783)
33. Hassan M., Feyen O., Grinstein E., Fas-induced apoptosis of renal cell carcinoma is mediated by apoptosis signal-regulating kinase 1 via mitochondrial damage-dependent caspase-8 activation. Cellular Oncology 2009 31 6 437 456 2-s2.0-71949085193 10.3233/CLO-2009-0488
34. Ferriola P. C., Cody V., Middleton E., Protein kinase C inhibition by plant flavonoids. Kinetic mechanisms and structure-activity relationships. Biochemical Pharmacology 1989 38 10 1617 1624 2-s2.0-0024550507 (Pubitemid 19120080)
35. Neckers L., Heat shock protein 90: the cancer chaperone. Journal of Biosciences 2007 32 3 517 530 2-s2.0-34248187981 10.1007/s12038-007-0051-y (Pubitemid 46708702)
36. Clark C. B., Rane M. J., El Mehdi D., Miller C. J., Sachleben L. R. Jr., Gozal E., Role of oxidative stress in geldanamycin-induced cytotoxicity and disruption of Hsp90 signaling complex. Free Radical Biology and Medicine 2009 47 10 1440 1449 2-s2.0-70350227307 10.1016/j.freeradbiomed.2009.08.012
37. Taiyab A., Sreedhar A. S., Rao C. M., Hsp90 inhibitors, GA and 17AAG, lead to ER stress-induced apoptosis in rat histiocytoma. Biochemical Pharmacology 2009 78 2 142 152 2-s2.0-65649113298 10.1016/j.bcp.2009.04.001
38. Sourbier C., Lindner V., Lang H., Agouni A., Schordan E., Danilin S., Rothhut S., Jacqmin D., Helwig J. J., Massfelder T., The phosphoinositide 3-kinase/Akt pathway: a new target in human renal cell carcinoma therapy. Cancer Research 2006 66 10 5130 5142 2-s2.0-33744902875 10.1158/0008-5472.CAN-05-1469 (Pubitemid 43844935)
39. Kao T. K., Ou Y. C., Lin S. Y., Pan H. C., Song P. J., Raung S. L., Lai C. Y., Liao S. L., Lu H. C., Chen C. J., Luteolin inhibits cytokine expression in endotoxin/cytokine-stimulated microglia. Journal of Nutritional Biochemistry 2011 22 7 612 624 2-s2.0-79955759334 10.1016/j.jnutbio.2010.01.011
40. Kim S. W., Kim H. J., Chun Y. J., Kim M. Y., Ceramide produces apoptosis through induction of p27kip1 by protein phosphatase 2A-dependent Akt dephosphorylation in PC-3 prostate cancer cells. Journal of Toxicology and Environmental Health A 2010 73 21-22 1465 1476 2-s2.0-77958168429 10.1080/15287394.2010.511553
41. Hostetter D. R., Loeb C. R. K., Chu F., Craik C. S., Hip is a pro-survival substrate of granzyme B. Journal of Biological Chemistry 2007 282 38 27865 27874 2-s2.0-34948883435 10.1074/jbc.M704312200 (Pubitemid 47529489)
42. Chen H., Xia Y., Fang D., Hawke D., Lu Z., Caspase-10-mediated heat shock protein 90 β cleavage promotes UVB irradiation-induced cell apoptosis. Molecular and Cellular Biology 2009 29 13 3657 3664 2-s2.0-67650084825 10.1128/MCB.01640-08
43. Robb V. A., Karbowniczek M., Klein-Szanto A. J., Henske E. P., Activation of the mTOR signaling pathway in renal clear cell carcinoma. Journal of Urology 2007 177 1 346 352 2-s2.0-33845309430 10.1016/j.juro.2006.08.076 (Pubitemid 44879483)
44. Motzer R. J., Escudier B., Oudard S., Hutson T. E., Porta C., Bracarda S., Grünwald V., Thompson J. A., Figlin R. A., Hollaender N., Urbanowitz G., Berg W. J., Kay A., Lebwohl D., Ravaud A., Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. The Lancet 2008 372 9637 449 456 2-s2.0-48649107474 10.1016/S0140-6736(08)61039-9
45. Cho D. C., Cohen M. B., Panka D. J., Collins M., Ghebremichael M., Atkins M. B., Signoretti S., Mier J. W., The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clinical Cancer Research 2010 16 14 3628 3638 2-s2.0-77954746352 10.1158/1078-0432.CCR-09-3022
46. Xu C. X., Li Y., Yue P., Owonikoko T. K., Ramalingam S. S., Khuri F. R., Sun S. Y., The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo. PLoS ONE 2011 6 6 2-s2.0-79958816470 10.1371/journal.pone.0020899 e20899
47. Cardillo M. R., Ippoliti F., Interleukin-6, interleukin-10 and heat shock protein-90 expression in renal epithelial neoplasias and surrounding normal-appearing renal parenchyma. International Journal of Immunopathology and Pharmacology 2007 20 1 37 46 2-s2.0-33947732393 (Pubitemid 46506874)
48. Hämäläinen M., Nieminen R., Vuorela P., Heinonen M., Moilanen E., Anti-inflammatory effects of flavonoids: Genistein, kaempferol, quercetin, and daidzein inhibit STAT-1 and NF- B activations, whereas flavone, isorhamnetin, naringenin, and pelargonidin inhibit only NF- B activation along with their inhibitory effect on iNOS expression and NO production in activated macrophages. Mediators of Inflammation 2007 2007 2-s2.0-34548562078 10.1155/2007/45673 45673 (Pubitemid 47388729)
49. Shimoi K., Okada H., Furugori M., Goda T., Takase S., Suzuki M., Hara Y., Yamamoto H., Kinae N., Intestinal absorption of luteolin and luteolin 7-O- β -glucoside in rats and humans. FEBS Letters 1998 438 3 220 224 2-s2.0-0031738302 10.1016/S0014-5793(98)01304-0 (Pubitemid 28529277)